Fideuram Intesa Sanpaolo Private Banking S.P.A. Buys New Holdings in Progyny, Inc. $PGNY

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 70,312 shares of the company’s stock, valued at approximately $1,806,000.

Other hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of Progyny by 57.1% in the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock worth $15,156,000 after buying an additional 256,078 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after buying an additional 235,513 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of Progyny by 336.0% in the third quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock worth $3,655,000 after buying an additional 130,885 shares during the last quarter. Algert Global LLC boosted its stake in shares of Progyny by 35.1% in the third quarter. Algert Global LLC now owns 595,805 shares of the company’s stock worth $12,822,000 after buying an additional 154,930 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after buying an additional 696,447 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of recent research reports. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating and issued a $30.00 target price on shares of Progyny in a research note on Friday, March 6th. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Citizens Jmp upped their target price on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Finally, Citigroup restated an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.55.

Insider Buying and Selling

In related news, CFO Mark S. Livingston sold 8,275 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total value of $211,012.50. Following the completion of the transaction, the chief financial officer owned 79,063 shares of the company’s stock, valued at approximately $2,016,106.50. This represents a 9.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa B. Cummings sold 9,578 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the transaction, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at $1,834,275. The trade was a 11.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 25,308 shares of company stock valued at $579,977. 9.90% of the stock is owned by company insiders.

Progyny Trading Up 0.8%

NASDAQ PGNY opened at $24.88 on Friday. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 32.31, a PEG ratio of 1.32 and a beta of 0.91. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $28.75. The stock has a 50-day moving average of $19.06 and a 200 day moving average of $22.03.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts predict that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.